Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Tislelizumab plus AG regimen for long-term CR in 2 patients with metastatic BRCA-mutation pancreatic cancer: A case report.

Medicine - 27 Dec 2024

Gao Feng, Xu Xue, Chen Chunhong, Lv Lili

Abstract excerpt

RATIONALE: An increased risk of pancreatic cancer (PC) is associated with breast cancer susceptibility gene (BRCA) mutations. Given limited therapies, there remains an urgent need to explore novel treatment strategies. PATIENT CONCERNS: We report 2 metastatic PC patients with BRCA mutations who initially did not respond to standard therapies. DIAGNOSES: Case 1 was diagnosed with metastatic PC harboring a BRCA1...

Read the complete abstract on PubMed

Topics

Humans
Pancreatic Neoplasms
Antineoplastic Combined Chemotherapy Protocols
Middle Aged
Female
Antibodies, Monoclonal, Humanized

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Mutation

Paclitaxel

Albumins

Oxaliplatin

BRCA2 Protein

Male

Aged

Phthalazines

Piperazines

Source

Open in PubMed Open full text

Identifiers

PMID: 39969335
DOI: 10.1097/MD.0000000000040997
PMCID: PMC11688073

Genes

PC
BRCA1
BRCA2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 25 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Tislelizumab plus AG regimen for long-term CR in 2 patients with metastatic BRCA-mutation pancreatic cancer: A case report.PMID 39969335Read ↗

Olaparib as a single agent treatment in pre-treated metastatic pancreatic cancer patient harboring BRCA2 mutation: What could we expect?Semantic proximity Read ↗

Multimodality therapy in metastatic pancreas cancer with a BRCA mutation and durable long-term outcome: biology, intervention, or both?Semantic proximity Read ↗

Exceptional Response to Olaparib and Pembrolizumab for Pancreatic Adenocarcinoma With Germline BRCA1 Mutation and High Tumor Mutation Burden: Case Report and Literature Review.Semantic proximity Read ↗

Anlotinib plus Tislelizumab for Recurrent Metastatic Pancreas Ductal Adenocarcinoma with Germline BRCA2 Mutation: A Case and Literature ReviewSemantic proximity Read ↗

BRCA-Mutated Pancreatic Cancer: From Discovery to Novel Treatment ParadigmsSemantic proximity Read ↗

Overcoming therapeutic resistance in pancreatic cancer: Emerging opportunities by targeting BRCAs and p53Semantic proximity Read ↗

Maintenance Olaparib for Germline BRCA -Mutated Metastatic Pancreatic CancerSemantic proximity Read ↗

A Somatic BRCA2-Mutated Pancreatic Adenocarcinoma With Sustained Exceptional Response to Modified FOLFIRINOXSemantic proximity Read ↗

Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers.Semantic proximity Read ↗

Addition of Ipatasertib to Dual Anti-HER2 Maintenance Therapy in HER2-Positive Metastatic Breast Tumors with PIK3CA Mutations: The Phase Ib SOLTI-1507 IPATHER Trial.Semantic proximity Read ↗

Targeting BRCA-mutant biliary tract cancer: Current evidence and future perspectives.Semantic proximity Read ↗

Toripalimab combined with albumin-paclitaxel plus gemcitabine as first-line treatment for locally advanced or metastatic pancreatic ductal adenocarcinoma: an open-label, phase Ib/II study and investigation of potential biomarkersSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.